A Sensor for Every Symptom: FDA Puts $1.1 Million Behind Digital Health in Drug Trials🔒 SSL Verified
Live Data Status: |E-commerce & Retail
Welcome to the detailed analysis for fdalawblog.net. This domain is officially recognized as FDA Law Blog. According to their official web presence, their primary focus is: "where experts go to learn about the FDA".
Table of Contents
- Tech Stack
- WordPressReact
- Link Profile
- Internal Pages: 16Outbound Links: 363
- Localization
- en
6-Month Traffic Trend Estimate
M1
M2
M3
M4
M5
M6
Estimated Market Value
$368,549
Based on domain age, authority, and keyword relevance.
TLD Availability Risk
- fdalawblog.comTaken
- fdalawblog.netTaken
- fdalawblog.orgTaken
- fdalawblog.ioAvailable
- fdalawblog.coAvailable
- fdalawblog.aiAvailable
Official Contact & Profiles
Content Snippets from fdalawblog.net
"On July 20, 2026, FDA posted a funding opportunity for sponsors putting digital health technologies (DHTs) to work in clinical trials. RFA-FD-26-012 is a U01 cooperative agreement with a $1.1 million award ceiling, two expected awards, and no cost-sharing requirement (Assistance Listing 93.103). Applications close August 20, 2026."
"The subject is DHTs, including actigraphy, photography, and contactless sensors, used for remote data acquisition in clinical investigations that support drug and biological product development. FDA lists four areas of interest (but notes the scope is non-exhaustive):"
"The Clinical Trials Optional designation in the announcement title widens the applicant pool. Under NIH policy, that designation permits an applicant to propose a clinical trial without requiring one, so a sponsor running a measurement comparison or endpoint development project with no trial underway remains eligible."
"FDA asked the public about this subject four months ago. Its March 2026 Request for Information sought comment on advancing DHT use in clinical investigations for drugs and biological products, with comments closing June 1. The Agency is now funding the work directly, consistent with CDER and CBER commitments under PDUFA VII to support DHT use in drug and biological product development."
Key Topics & Focus Areas for fdalawblog.net:
Authority Metrics: Score 76/100
Global Reach of Fdalawblog
Competitor Analysis for .NET Domains
By comparing fdalawblog.net to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to fdalawblog.net.
Frequently Asked Questions
Is fdalawblog.net a safe and secure website?
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
What is the authority score of fdalawblog.net?
As of August 4, 2026, fdalawblog.net holds an estimated domain authority score of 81/100 based on our VisitRank tracking algorithms.
What are the top alternatives to fdalawblog.net?
You can find the best alternatives and similar sites to fdalawblog.net in our explore section, which includes competitors in the E-commerce & Retail sector.
Data Sources & Methodology: DNS telemetry and routing records are resolved via live root servers. Market valuation estimates are computed algorithmically based on proprietary historical indexation multiples and standardized digital asset appraisal methodologies.
Common Misspellings & Typo Domains for fdalawblog.net:
fadlawblog.netfdlawblog.netfddalawblog.netfdelawblog.netfdalewblog.netfdalawblog.netfsalawblog.netfealawblog.net